LGALS3 and hepatocellular carcinoma: Galectin-3 is also upregulated in patients with cirrhosis and hepatocellular carcinoma, and its high expression correlates with immune infiltration, invasion, metastasis, and poor prognosis in hepatocellular carcinoma patients [36,37,38,39].